Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Sophia Ish-Shalom, Constantin Dumitrache, Timour Fikry El-Husseini, Azza Hussein, Clare Barker & Imre Pavo. (2011) Postmenopausal women with osteoporosis: experience when treated with teriparatide in clinical practice. Current Medical Research and Opinion 27:2, pages 343-353.
Read now
Read now
George Lyritis, Fernando Marin, Clare Barker, Michael Pfeifer, Jordi Farrerons, Kim Brixen, Javier del Pino, Richard Keen & Thomas N. Nickelsen. (2010) Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS. Current Medical Research and Opinion 26:8, pages 1799-1807.
Read now
Read now
S. Scharla, H. Oertel, K. Helsberg, F. Kessler, F. Langer & T. Nickelsen. (2006) Skeletal pain in postmenopausal women with osteoporosis: prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration. Current Medical Research and Opinion 22:12, pages 2393-2402.
Read now
Read now
Articles from other publishers (42)
Marie‐Eva Pickering, Rose‐Marie Javier, Sandrine Malochet, Gisele Pickering & Jules Desmeules. (2023) Osteoporosis treatment and pain relief: A scoping review. European Journal of Pain 28:1, pages 3-20.
Crossref
Crossref
Pun Yuet Lam, Prudence Wing Hang Cheung, Sin Ting Lau & Jason Pui Yin Cheung. (2022) Quality of life of postmenopausal women with teriparatide, denosumab and alendronate: One-year prospective study with a propensity score-matched comparison. Journal of Orthopaedics, Trauma and Rehabilitation 30:1.
Crossref
Crossref
Masayuki Miyagi, Gen Inoue, Kosuke Murata, Tomohisa Koyama, Akiyoshi Kuroda, Ayumu Kawakubo, Yuji Yokozeki, Yusuke Mimura, Yuta Nanri, Kazuhide Inage, Tsutomu Akazawa, Seiji Ohtori, Kentaro Uchida & Masashi Takaso. (2021) Factors associated with pain-related disorders and gait disturbance scores from the Japanese orthopedic association back pain evaluation questionnaire and Oswestry Disability Index in patients with osteoporosis. Archives of Osteoporosis 17:1.
Crossref
Crossref
John H Krege, Alicia W Gilsenan, John L Komacko & Nicole Kellier‐Steele. (2022) Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates. JBMR Plus 6:9.
Crossref
Crossref
Nimesh Patel, Mohamed Fayed, Priyansh Faldu, Wissam Maroun & Janki Chandarana. (2022) Chronic Proton-Pump Inhibitor Therapy and Fracture Risk in Women Aged Between 50 and 65 years: A Retrospective Case-Control Study. Cureus.
Crossref
Crossref
N. O. Khovasova, E. N. Dudinskaya, A. V. Naumov, O. N. Tkacheva, L. V. Machekhina & Ju. S. Onuchina. (2022) Effect of bone anabolic therapy on bone remodeling and bone density in geriatric patients with osteoporosis and falling syndrome. Problems of Endocrinology 68:3, pages 67-75.
Crossref
Crossref
Fernando Marin & Yanfei L. Ma. 2022. Osteoporotic Fracture and Systemic Skeletal Disorders. Osteoporotic Fracture and Systemic Skeletal Disorders
339
359
.
Takahiro Mori, Carolyn J. Crandall, Tomoko Fujii & David A. Ganz. (2021) Cost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan. Archives of Osteoporosis 16:1.
Crossref
Crossref
Takashi Hara, Yasukazu Hijikata, Yukiko Matsubara & Norio Watanabe. (2021) Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D. Cochrane Database of Systematic Reviews 2021:7.
Crossref
Crossref
海铭 李. (2021) Effects of Teriparatide (PTH 1-34) and Zoledronic Acid on Postmenopausal Osteoporotic Patients with Low Bone Turnover. Advances in Clinical Medicine 11:06, pages 2670-2677.
Crossref
Crossref
Cristina Carbonell Abella & Daniel Martínez Laguna. (2020) Fractura aplastamiento vertebral por fragilidad. FMC - Formación Médica Continuada en Atención Primaria 27:7, pages 320-328.
Crossref
Crossref
Tomoya Tanaka, Ryoko Takao-Kawabata, Aya Takakura, Yukari Shimazu, Momoko Nakatsugawa, Akitoshi Ito, Ji-Won Lee, Koh Kawasaki & Tadahiro Iimura. (2020) Teriparatide relieves ovariectomy-induced hyperalgesia in rats, suggesting the involvement of functional regulation in primary sensory neurons by PTH-mediated signaling. Scientific Reports 10:1.
Crossref
Crossref
Sho Kato, Hiroki Wakabayashi, Taro Nakagawa, Gaku Miyamura, Yohei Naito, Takahiro Iino & Akihiro Sudo. (2019) Teriparatide improves pain-related behavior and prevents bone loss in ovariectomized mice. Journal of Orthopaedic Surgery 28:1, pages 230949901989319.
Crossref
Crossref
Fumitoshi Omura. (2019) Impact of patient background factors on the treatment efficacy of once-weekly teriparatide. Osteoporosis and Sarcopenia 5:2, pages 51-56.
Crossref
Crossref
Bente L. Langdahl, Stuart Silverman, Saeko Fujiwara, Ken Saag, Nicola Napoli, Satoshi Soen, Hiroyuki Enomoto, Thomas E. Melby, Damon P. Disch, Fernando Marin & John H. Krege. (2018) Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies. Bone 116, pages 58-66.
Crossref
Crossref
Nicola Napoli, Bente. L. Langdahl, Östen Ljunggren, Eric Lespessailles, George Kapetanos, Tomaz Kocjan, Tatjana Nikolic, Pia Eiken, Helmut Petto, Thomas Moll, Erik Lindh & Fernando Marin. (2018) Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS). Calcified Tissue International 103:4, pages 359-371.
Crossref
Crossref
. (2018) Manage osteoporotic pain by treating osteoporosis and taking a multidimensional approach to pain management. Drugs & Therapy Perspectives 34:7, pages 311-315.
Crossref
Crossref
R. Vellucci, R. Terenzi, J. A Kanis, H. G. Kress, R. D. Mediati, J.-Y. Reginster, R. Rizzoli & M. L. Brandi. (2018) Understanding osteoporotic pain and its pharmacological treatment. Osteoporosis International 29:7, pages 1477-1491.
Crossref
Crossref
Antonino Catalano, Gabriella Martino, Nunziata Morabito, Claudia Scarcella, Agostino Gaudio, Giorgio Basile & Antonino Lasco. (2017) Pain in Osteoporosis: From Pathophysiology to Therapeutic Approach. Drugs & Aging 34:10, pages 755-765.
Crossref
Crossref
Ivo K. GenevMatthew K. TobinSaher P. Zaidi, Sajeel R. Khan, Farid M. L. Amirouche & Ankit I. Mehta. (2017) Spinal Compression Fracture Management. Global Spine Journal 7:1, pages 71-82.
Crossref
Crossref
Bente L. Langdahl, Östen Ljunggren, Claude-Laurent Benhamou, Fernando Marin, George Kapetanos, Tomaz Kocjan, Eric Lespessailles, Nicola Napoli, Tatjana Nikolic, Helmut Petto, Thomas Moll & Erik Lindh. (2016) Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS). Calcified Tissue International 99:3, pages 259-271.
Crossref
Crossref
Fergus E. McKiernan. (2016) Violet Fox: A Clinical View of Vertebral Fractures. Journal of Clinical Densitometry 19:1, pages 35-39.
Crossref
Crossref
Kyoung Min Lee, Chin Youb Chung, Soon-Sun Kwon, Tae Gyun Kim, In Hyeok Lee, Ki Jin Jung, Jin Woo Park, Sang Young Moon & Moon Seok Park. (2014) Bone mineral density is not associated with musculoskeletal pain in postmenopausal Korean women aged ≥50 years. Clinical Rheumatology 34:2, pages 337-343.
Crossref
Crossref
O. Lamy, B. Uebelhart & B. Aubry-Rozier. (2013) Risks and benefits of percutaneous vertebroplasty or kyphoplasty in the management of osteoporotic vertebral fractures. Osteoporosis International 25:3, pages 807-819.
Crossref
Crossref
Östen Ljunggren, Annabel Barrett, Ivaylo Stoykov, Bente L Langdahl, Willem F Lems, J Bernard Walsh, Astrid Fahrleitner-Pammer, Gerald Rajzbaum, Franz Jakob, Dimitrios Karras & Fernando Marin. (2013) Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study. BMC Musculoskeletal Disorders 14:1.
Crossref
Crossref
Daniel R. Murphy, Robert W. Klein, Lee J. Smolen, Timothy M. Klein & Stephen D. Roberts. (2013) Using Common Random Numbers in Health Care Cost-Effectiveness Simulation Modeling. Health Services Research 48:4, pages 1508-1525.
Crossref
Crossref
Daniel R Murphy, Lee J Smolen, Timothy M Klein & Robert W Klein. (2012) The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden. BMC Musculoskeletal Disorders 13:1.
Crossref
Crossref
P. Hadji, J. R. Zanchetta, L. Russo, C. P. Recknor, K. G. Saag, F. E. McKiernan, S. L. Silverman, J. Alam, R. T. Burge, J. H. Krege, M. C. Lakshmanan, D. N. Masica, B. H. Mitlak & J. L. Stock. (2011) The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporosis International 23:8, pages 2141-2150.
Crossref
Crossref
Y.-Y. Tseng, C.-H. Su, T.-N. Lui, Y.-S. Yeh & S.-H. Yeh. (2011) Prospective comparison of the therapeutic effect of teriparatide with that of combined vertebroplasty with antiresorptive agents for the treatment of new-onset adjacent vertebral compression fracture after percutaneous vertebroplasty. Osteoporosis International 23:5, pages 1613-1622.
Crossref
Crossref
Po-Hsun Tu, Zhuo-Hao Liu, Shih-Tseng Lee & Jyi-Feng Chen. (2012) Treatment of repeated and multiple new-onset osteoporotic vertebral compression fractures with teriparatide. Journal of Clinical Neuroscience 19:4, pages 532-535.
Crossref
Crossref
Jane A Cauley, Dennis Black, Steven Boonen, Steven R Cummings, Peter Mesenbrink, Lisa Palermo, Zulema Man, Peyman Hadji & Ian R Reid. (2011) Once-yearly zoledronic acid and days of disability, bed rest, and back pain: Randomized, controlled HORIZON Pivotal Fracture Trial. Journal of Bone and Mineral Research 26:5, pages 984-992.
Crossref
Crossref
Bente L. Langdahl, Gerald Rajzbaum, Franz Jakob, Dimitrios Karras, Östen Ljunggren, Willem F. Lems, Astrid Fahrleitner-Pammer, J. Bernard Walsh, Clare Barker, Alexey Kutahov & Fernando Marin. (2009) Reduction in Fracture Rate and Back Pain and Increased Quality of Life in Postmenopausal Women Treated with Teriparatide: 18-Month Data from the European Forsteo Observational Study (EFOS). Calcified Tissue International 85:6, pages 484-493.
Crossref
Crossref
R. Lindsay, P. Miller, G. Pohl, E. V. Glass, P. Chen & J. H. Krege. (2008) Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporosis International 20:6, pages 943-948.
Crossref
Crossref
Fergus Eoin McKiernan. (2009) The broadening spectrum of osteoporotic vertebral fracture. Skeletal Radiology 38:4, pages 303-308.
Crossref
Crossref
R. M. Francis, T. J. Aspray, G. Hide, A. M. Sutcliffe & P. Wilkinson. (2007) Back pain in osteoporotic vertebral fractures. Osteoporosis International 19:7, pages 895-903.
Crossref
Crossref
Paul D. Miller. (2008) Safety of parathyroid hormone for the treatment of osteoporosis. Current Osteoporosis Reports 6:1, pages 12-16.
Crossref
Crossref
Stephanie K A Blick, Sohita Dhillon & Susan J Keam. (2008) Teriparatide. Drugs 68:18, pages 2709-2737.
Crossref
Crossref
S. Manuele, L. Sorbello, N. Puglisi, S. Grasso, L. La Malfa, G. D’Urbino, M. Rizzotto, S. Strano & D. Maugeri. (2007) The teriparatide in the treatment of severe senile osteoporosis. Archives of Gerontology and Geriatrics 44, pages 249-258.
Crossref
Crossref
P. Vestergaard, N. R. Jorgensen, L. Mosekilde & P. Schwarz. (2006) Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk – a meta-analysis. Osteoporosis International 18:1, pages 45-57.
Crossref
Crossref
M. C. Nevitt, P. Chen, D. P. Kiel, J.-Y. Reginster, R. K. Dore, J. R. Zanchetta, E. V. Glass & J. H. Krege. (2006) Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Osteoporosis International 17:11, pages 1630-1637.
Crossref
Crossref
Françoise Debiais & Géraldine Durand. (2006) Le tériparatide. Revue du Rhumatisme 73:8, pages 838-845.
Crossref
Crossref
Michael C. Nevitt, Peiqi Chen, Robin K. Dore, Jean-Yves Reginster, Douglas P. Kiel, Jose R. Zanchetta, Emmett V. Glass & John H. Krege. (2005) Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporosis International 17:2, pages 273-280.
Crossref
Crossref